Under Israel Law, once allowed by an Examiner, a patent application publishes and oppositions may be filed within three months of publication. Grounds for opposition including, inter alia, lack of novelty, obviousness, that the opposer and not the applicant is the true inventor.
In the cases in question are IL 131392 and it’s divisionals: IL166189 and IL 166550, and IL 135898, all relating to addition of hydrogen about the C=C double bond of thiazolidinedione TZD in the production of Rosiglitazone, with IL 131392 and IL166189 and IL 166550 relating to use of the relatively gentle borohydride reducing agent on the thiazolidinedione and IL 135898 relating to achieving the same product by reacting the with hydrogen in the presence of a palladium on carbon catalyst under Read the rest of this entry »
Posted by Dr Michael Factor 
In the 2009 General Meeting on Sunday, in her overview of activities of the Association of Patent Attorneys in Israel, outgoing chairperson, Ms. Michal Hackmey, pointed out that since it was a voluntary professional body, the Association of Patent Attorneys in Israel lacked the teeth to be able to enforce decisions, and that many practitioners weren’t members.
